Entero Therapeutics, Inc. (NASDAQ: ENTO) announced a 1 for 3 reverse stock split of its common stock to comply with Nasdaq listing requirements.
The stock split will reduce outstanding shares from 4.77 million to approximately 1.59 million.
Trading on a split-adjusted basis will start on August 18, 2025, enhancing the company's market visibility and credibility.
Reverse Stock Split Details
The reverse stock split ratio is 1 for 3, meaning every 3 shares will be combined into 1 share.
Trading Commencement Date
The split-adjusted trading on Nasdaq Capital Market begins on August 18, 2025.
Treatment of Fractional Shares
Stockholders will receive cash in lieu of fractional shares resulting from the reverse stock split.
- The reverse stock split will reduce the outstanding common stock from 4.77 million shares to approximately 1.59 million shares.
- The split is part of the company's plan to comply with Nasdaq's listing requirements, specifically the minimum bid price of $1.00 per share.
The reverse stock split by Entero Therapeutics, Inc. aims to maintain its Nasdaq listing and enhance shareholder value. This strategic move aligns with the company's goal of developing innovative therapies for gastrointestinal diseases.